Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Semtech Corporation Common Stock (SMTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Semtech Corporation Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Semtech Corporation Common Stock trades at $155.12 (market cap $16.12B). The key difference: Semtech Corporation Common Stock is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is more actively traded (779,107 versus 3,682,647). Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Semtech Corporation Common Stock for 2 Days on average.
| KYMR | SMTC | |
|---|---|---|
Market Cap | $8.87B | $16.12B |
Volume | 779,107 | 3,682,647 |
Sector | Health | Technology |
52-Week High | $127.31 | $197.20 |
52-Week Low | $55.80 | $62.57 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $8.26B | $16.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SMTC trades at $172.78, up 2.67% today, with a bullish technical setup near its pivot point of $173. The stock has gained 154% year-to-date, driven by strong AI data center demand and recent earnings beats. Revenue is projected to grow from $909 million in 2025 to $1.2 billion in 2026, with net income turning positive. Analysts maintain a strong buy consensus with an average price target of $216.38.
Outlook is positive given robust AI-driven growth and expanding partnerships, but high valuation multiples and recent insider selling pose risks. The stock's momentum hinges on continued execution in data center markets and the upcoming Q3 2026 earnings report.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Semtech Corporation Common Stock
Semtech develops analog and mixed-signal semiconductors and connectivity products. Its technologies are used in communications, data centers, industrial systems, and IoT devices.
Read more on SMTC →
